Britain's pharmaceutical industry is sounding the alarm over a dramatic collapse in research investment that threatens the country's status as a global life sciences hub. New figures reveal the UK's share of worldwide pharmaceutical research and development funding has crashed from 7% in 2012 to just 2% today – a decline that could have serious implications for patients' access to breakthrough treatments.
The Association of the British Pharmaceutical Industry (ABPI) warns this sharp drop stems largely from the current medicines pricing system, which creates an unpredictable business environment that deters companies from investing in UK research. The voluntary scheme for branded medicines pricing and access (VPAS), designed to control NHS drug costs, is inadvertently pushing pharmaceutical investment overseas, according to industry leaders.
The stakes are considerable. The pharmaceutical sector supports approximately 77,000 jobs across Britain and contributes £30 billion in economic value. Yet the UK has tumbled from 4th to 10th place globally for clinical trials since 2017 – a concerning trend that not only slows medical progress but limits patients' opportunities to access cutting-edge treatments through research programmes.
The ABPI is calling for a fundamental overhaul of the current framework, proposing a new long-term system that balances innovation incentives with NHS affordability. Their vision includes improved patient access to new medicines whilst ensuring the UK remains an attractive destination for pharmaceutical investment and research.
With the current VPAS agreement expiring at the end of 2023, negotiations for its replacement are now underway. The timing makes this debate particularly urgent, as decisions made in the coming months will determine whether Britain can reverse its declining position in global pharmaceutical research or risks further erosion of its once-dominant life sciences sector.
For patients, the ultimate concern is clear: without a thriving research environment, access to tomorrow's life-saving treatments may increasingly depend on decisions made in other countries. The challenge now is finding a pricing system that protects NHS budgets whilst maintaining the UK's appeal as a world-leading centre for medical innovation.